JAK2 expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: Implications for evaluating JAK2 inhibitors

Cancer Immunology Research

Volumn 2, Issue 4, 2014, Pages 301-306

  Miller, Chris P ^a   Thorpe, Jason D ^b   Kortum, Amanda N ^a   Coy, Catherine M ^a   Cheng, Wei Yi ^d   Yang, Tai Hsien Ou ^d   Anastassiou, Dimitris ^d   Beatty, J David ^b,c   Urban, Nicole D ^b   Blau, C Anthony ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MESSENGER RNA; PROTEIN KINASE INHIBITOR;

ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MORTALITY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; JANUS KINASE 2; LYMPHOCYTES, TUMOR-INFILTRATING; PROTEIN KINASE INHIBITORS; RECURRENCE; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84907074309     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0189     Document Type: Article

References (29)

1. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-95.
2. Wagner KU, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 2004; 24: 5510-20.
3. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-35.
4. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 2013; 73: 3470-80.
5. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012; 22: 796-811.
6. + breast cancer. J Clin Oncol 2013; 31: (suppl; abstr TPS1134).
7. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
9. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
11. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
12. Cheng WY, Ou Yang TH, Anastassiou D. Development of a prognostic model for breast cancer survival in an open challenge environment. Sci Transl Med 2013; 5: 181ra50.
13. Cheng WY, Ou Yang TH, Anastassiou D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 2013; 9: e1002920.
14. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-52.
15. McCarthy N. Prognostic models: rising to the challenge. Nat Rev Cancer 2013; 13: 378.
16. Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graphical Stat 2006; 15: 609-27.
17. Team RDC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. ISBN 3-900051-07-0. Available from: http://www.R-project.org/.
18. Halekoh U. Højsgaard S, Yan J. The R package geepack for generalized estimating equations. J Stat Softw 2006; 15: 1-11.
19. Pencina MJ. D'Agostino RB. Stat Med 2004; 23: 2109-23.
20. Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, et al. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells 2009; 27: 2353-61.
21. Kohlhuber F, Rogers NC, Watling D, Feng J, Guschin D, Briscoe J, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol 1997; 17: 695-706.
22. + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-55.
23. Cheng W, Ou Yang TH, Shen H, Laird PW, Anastassiou D, and The Cancer Genome Atlas. Multi-cancer molecular signatures and their interrelationships. arXiv: 2013; 1306.2584v2.
24. Pardoll D. Metastasis-promoting immunity: when T cells turn to the dark side. Cancer Cell 2009; 16: 81-2.
25. Miller CP, Urban N, Blau CA. Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors. Anticancer Res 2011; 31: 1189-95.
26. Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O'Shea JJ, Johnston JA. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995; 181: 399-404.
27. Watling D, Guschin D, Muller M, Silvennoinen O, Witthuhn BA, Quelle FW, et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 1993; 366: 166-70.
28. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010; 184: 5298-307.
29. Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 2012; 120: 4093-103.